Document Detail

Spontaneous rectus muscle hematoma following streptokinase therapy for acute myocardial infarction: a case report.
MedLine Citation:
PMID:  12104074     Owner:  NLM     Status:  MEDLINE    
There is no doubt that appropriate use of thrombolytic drugs improves survival in patients with acute myocardial infarction. Streptokinase, one of the most commonly used thrombolytic drugs in large clinical trials, is not fibrin-specific and brings about a lytic state with potential for bleeding. We report a case of spontaneous rectus muscle hematoma following streptokinase therapy for acute myocardial infarction and review the relevant literature. To our knowledge, this is the first case reported in the literature.
Mehmet Birhan Yilmaz; Yesim Akin; Umit Güray; Halil Kisacik; Sule Korkmaz
Related Documents :
21370304 - Fetal heart ventricle mass obtained by stic acquisition combined with inversion mode an...
3521234 - Coronary thrombolytic therapy: state of the art.
10980844 - Current state of thrombolytic therapy.
10392224 - Case report: reversal of an evolving myocardial infarction with intravenous thrombolysis.
19242324 - Percutaneous left ventricular assist in ischemic cardiac arrest.
1692444 - Myocardial ischemia, reperfusion and free radical injury.
Publication Detail:
Type:  Case Reports; Letter; Review    
Journal Detail:
Title:  International journal of cardiology     Volume:  84     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-09     Completed Date:  2002-09-26     Revised Date:  2006-07-12    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  101-3     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fibrinolytic Agents / adverse effects*,  therapeutic use
Hematoma / chemically induced*
Middle Aged
Myocardial Infarction / drug therapy*
Rectus Abdominis*
Streptokinase / adverse effects*,  therapeutic use
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of speech therapy with poetry on heart rate rhythmicity and cardiorespiratory coordination.
Next Document:  Application of tandem mass spectrometry to biochemical genetics and newborn screening.